|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We also performed HRM analysis on breast tumour DNA samples with unknown TP53 mutation status.
|
17764544 |
2007 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Immunohistochemical analysis of breast tumors from these patients revealed high levels of mutant p53 protein, suggesting a functional mutation in the p53 gene.
|
10706125 |
2000 |
|
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
|
23657012 |
2013 |
|
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Previously, we found that p53 genotype was correlated with ER expression and response to tamoxifen in mammary tumors arising in mouse mammary tumor virus-Wnt-1 transgenic mice.
|
19351845 |
2009 |
|
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
However, whereas the majority of sporadic breast tumors that stained negative for p53 accumulation had wild-type TP53, the majority of BRCA1-associated breast tumors that stained negative for p53 accumulation had protein-truncating TP53 mutations (nonsense, frameshift, and splice mutations).
|
19336573 |
2009 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
These results indicate that these biochemically defined domains also have biological relevance in terms of breast cancer disease course, and suggest that some mutations in TP53, more than others, can contribute to the development of clinically more aggressive and perhaps treatment resistant breast tumours.
|
8527388 |
1995 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
One hundred thirty-eight (35%) of the breast tumors had p53 mutations, of which 88% were located in exons 5 to 8.
|
16434591 |
2006 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Our data indicate that p53 mutations are frequent in breast tumours associated with unfavorable prognosis, including high-grade or the comedo histotype.
|
9428925 |
1997 |
|
Mammary Neoplasms
|
0.700 |
PosttranslationalModification
|
group |
BEFREE |
From our laboratory we have recently reported rearrangement only in the coding region of the p53 gene in breast tumors.
|
10690643 |
1999 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Comparison of DGGE and immunohistochemistry in the detection of TP53 variants in a Brazilian sample of sporadic breast tumors.
|
21107729 |
2011 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
These results suggest that breast tumours with mutations in BRCA2 or TP53 could be promising candidates for Aurora-A targeted treatment.
|
16860930 |
2007 |
|
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Through search for other possible p53 E3 ligases by mRNA and protein expression analysis, downregulation of TNF receptor-associated factor 7 (TRAF7) expression was found in these breast tumors.
|
23128672 |
2013 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
It is known that both genetic and environmental factors are important for breast carcinogenesis and that structural and/or functional alterations at p53 gene are commonly observed in breast tumors.
|
11024482 |
2000 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The principal aim of this study was to study the concordance of RNA- and DNA-based direct sequencing methods in detecting p53 mutations in breast tumors.
|
9510848 |
1998 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The p53 gene mutations have been associated with the development of human breast and canine mammary neoplasms; breast carcinoma patients with alterations of p53 gene are considered to have a poor prognosis.
|
11299814 |
2001 |
|
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
We are able to recognise six different classes of p53 expression pattern that may be of help in the subclassification of breast tumours.
|
1569122 |
1992 |
|
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Our results show that centrosome amplification can arise independent of ER or p53 status and is a common feature of aneuploid breast tumors.
|
12500932 |
2002 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We found that the high incidence of protein truncating TP53 mutations and the pattern and amount of genomic aberrations specific for BRCA1-mutated breast tumors are also characteristic for BLBCs and different from luminal breast tumors.
|
21118481 |
2010 |
|
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
The p53 status is the most probable reason leading to differential LDIR biological activities between breast tumor cells and normal breast cells.
|
27959407 |
2017 |
|
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
CGH analysis of breast tumours in conjunction with telomerase status has supported early results suggesting the involvement of the telomerase hTR, c-myc and p53 genes in the control of telomerase activity.
|
10502730 |
1999 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Our results suggest that gene-smoking and gene-gene interactions may impact the prevalence of p53 mutations in breast tumors.
|
17683074 |
2008 |
|
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
The current studies were designed to characterize the accelerated senescence response to radiation in the breast tumour cell in terms of its dependence on functional p53 and its relationship to telomerase activity, telomere lengths, expression of human telomerase reverse transcriptase (hTERT, the catalytic subunit of telomerase) and human telomerase RNA (hTR, the RNA subunit of telomerase), as well as the induction of cytogenetic aberrations.
|
16308915 |
2005 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations.
|
20482849 |
2010 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Using PCR-based analysis, we were able to demonstrate p53 allelic losses in three of six breast tumors from heterozygote patients tested.
|
8502490 |
1993 |
|
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Finally, mutations in the p53 gene are inherited in families with Li-Fraumeni syndrome, a rare cancer syndrome predisposing to breast tumors, sarcomas, leukemia and other cancers.
|
8116068 |
1993 |